FDA keeps Sol­id Bio's trou­bled Duchenne MD gene ther­a­py on clin­i­cal lock­down in lat­est set­back

Much-ma­ligned Sol­id Bio­sciences re­ceived yet an­oth­er spate of bad news late Fri­day re­gard­ing its Duchenne mus­cu­lar dy­s­tro­phy gene ther­a­py pro­gram.

It’s been al­most nine months …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER